DDInter704 DDInter474
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Osteopenia
Osteopenia {u} (Side Effect) is caused by {v} (Compound) Aripiprazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Everolimus {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) UGT2B7
UGT2B7 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Everolimus (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Dapagliflozin (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Everolimus (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Everolimus (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Everolimus (Compound) causes Osteopenia (Side Effect) and Osteopenia (Side Effect) is caused by Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Everolimus (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with UGT2B7 (Gene) and UGT2B7 (Gene) is bound by Dapagliflozin (Compound)